Optimizing Value from Cardiac Rehabilitation A Cost-Utility Analysis Comparing Age, Sex, and Clinical Subgroups

Mayo Clinic Proceedings

Volumn 90, Issue 8, 2015, Pages 1011-1020

  Leggett, Laura E ^a,b   Hauer, Trina ^c   Martin, Billie Jean ^e   Manns, Braden ^a,b,e   Aggarwal, Sandeep ^c,e   Arena, Ross ^c,f   Austford, Leslie D ^c   Meldrum, Don ^c,e   Ghali, William ^a,b,e   Knudtson, Merril L ^e   Norris, Colleen M ^d,g   Stone, James A ^c,e   Clement, Fiona ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c TotalCardiology Rehabilitation and Risk Reduction   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGE; AGE DISTRIBUTION; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEART REHABILITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT REFERRAL; PROGRAM EVALUATION; QUALITY OF LIFE; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; UNSTABLE ANGINA PECTORIS; AGED; COMPLICATION; ECONOMICS; MORTALITY; MYOCARDIAL INFARCTION; QUALITY ADJUSTED LIFE YEAR; REHABILITATION CENTER; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; CARDIAC CATHETERIZATION; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; REHABILITATION CENTERS; RISK FACTORS; SEX FACTORS;

EID: 84938742065     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.05.015     Document Type: Article

References (31)

1. B.S. Heran, J.M. Chen, S. Ebrahim, and et al. Exercise-based cardiac rehabilitation for coronary heart disease [review] Cochrane Database Syst Rev 7 2011 CD001800
2. R. Arena Lifestyle modification interventions and cardiovascular health: global perspectives on worksite health and wellness and cardiac rehabilitation Prog Cardiovasc Dis 56 5 2014 473 475
3. National Heart, Lung, and Blood Institute What Is Cardiac Rehabilitation? 2012 National Heart, Lung and Blood Institute Bethesda, MD
4. P.R. Lawler, K.B. Filion, and M.J. Eisenberg Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: a systematic review and meta-analysis of randomized controlled trials Am Heart J 162 4 2011 571 584
5. R.S. Taylor, A. Brown, S. Ebrahim, and et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials Am J Med 116 10 2004 682 692
6. W. Wong, J. Feng, K. Pwee, and J. Lim A systematic review of economic evaluations of cardiac rehabilitation BMC Health Serv Res 12 1 2012 243
7. R. Robinson Cost-utility analysis BMJ 307 6908 1993 859 862
8. M. Drummond, M. Sculpher, G. Torrance, B. O'Brien, and Stoddart Methods for Economic Evaluation of Health Care Programmes 2005 Oxford Medical Publication New York, NY
9. Canadian Agency for Drugs and Technologies in Health Guidelines for the Economic Evaluation of Health Technologies: Canada 3rd ed. 2006 Canadian Agency for Drugs and Technologies in Health Ottawa, Ontario
10. W.A. Ghali, M.L. Knudtson on behalf of the APPROACH investigators Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Can J Cardiol 16 10 2000 1225 1230
11. The EuroQol Group What is EQ-5D? 2013 The EuroQol Group Rotterdam, the Netherland
12. F.M. Shrive, W.A. Ghali, J.A. Johnson, C. Donaldson, and B.J. Manns Use of the US and UK Scoring Algorithm for the EuroQol-5D in an Economic Evaluation of Cardiac Care Med Care 45 3 2007 269 273
13. F.M. Shrive, B.J. Manns, P.D. Galbraith, M.L. Knudtson, W.A. Ghali for the APPROACH Investigators Economic evaluation of sirolimus-eluting stents CMAJ 172 3 2005 345 351
14. Statistics Canada Consumer Price Index, Historical Summary (1994 to 2013) 2014 Statistics Canada Ottawa, Ontario
15. B.J. Martin, T. Hauer, R. Arena, and et al. Cardiac rehabilitation attendance and outcomes in coronary artery disease patients Circulation 126 6 2012 677 687
16. A. Briggs Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty Value Health 8 1 2005 1 2
17. N. Oldridge, W. Furlong, D. Feeny, and et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction Am J Cardiol 72 2 1993 154 161
18. C.M. Yu, C.P. Lau, J. Chau, and et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention Arch Phys Med Rehabil 85 12 2004 1915 1922
19. J.A. Suaya, D.S. Shepard, S.L. Normand, P.A. Ades, J. Prottas, and W.B. Stason Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery Circulation 116 15 2007 1653 1662
20. Colbert JD, Martin BJ, Haykowsky MJ, et al. Cardiac rehabilitation referral, attendance and mortality in women [published online October 2, 2014]. Eur J Prev Cardiol.
21. A.R. Menezes, C.J. Lavie, R.V. Milani, D.E. Forman, M. King, and M.A. Williams Cardiac rehabilitation in the United States Prog Cardiovasc Dis 56 5 2014 522 529
22. S.L. Grace, S. Bennett, C.I. Ardern, and A.M. Clark Cardiac rehabilitation series: Canada Prog Cardiovasc Dis 56 5 2014 530 535
23. J.S. Pliskin, W.B. Stason, M.C. Weinstein, and et al. Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis Med Decis Making 1 1 1981 10 28
24. M.C. Weinstein, and W.B. Stason Cost-effectiveness of coronary artery bypass surgery Circulation 66 5, pt 2 1982 III56 III66
25. D.K. Owens, G.D. Sanders, R.A. Harris, and et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death Ann Intern Med 126 1 1997 1 12
26. P.B. Sandesara, C.T. Lambert, N.F. Gordon, and et al. Cardiac rehabilitation and risk reduction: time to "rebrand and reinvigorate." J Am Coll Cardiol 65 4 2015 389 395
27. M. Drummond, B. Evans, J. LeLorier, and et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology Can J Clin Pharmacol 16 2 2009 e273 e281
28. C. McCabe, K. Claxton, and A. Tsuchiya Orphan drugs and the NHS: should we value rarity? BMJ 331 7523 2005 1016 1019
29. J. Prevot, and D. Watters HTA's and access to rare diseases therapies: the view from the PID community Pharm Policy Law 13 3 2011 177 181
30. B.J. Martin, R. Arena, M. Haykowsky, et al. APPROACH, Investigators Cardiovascular fitness and mortality after contemporary cardiac rehabilitation Mayo Clinic Proc 88 5 2013 455 463
31. B.A. Franklin, C.J. Lavie, R.W. Squires, and R.V. Milani Exercise-based cardiac rehabilitation and improvements in cardiorespiratory fitness: implications regarding patient benefit Mayo Clinic Proc 88 5 2013 431 437